Improving Response Inhibition in Parkinson’s Disease with Atomoxetine

BACKGROUND: Dopaminergic drugs remain the mainstay of Parkinson’s disease therapy but often fail to improve cognitive problems such as impulsivity. This may be due to the loss of other neurotransmitters, including noradrenaline, which is linked to impulsivity and response inhibition. We therefore ex...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Biol Psychiatry
Main Authors: Ye, Zheng, Altena, Ellemarije, Nombela, Cristina, Housden, Charlotte R., Maxwell, Helen, Rittman, Timothy, Huddleston, Chelan, Rae, Charlotte L., Regenthal, Ralf, Sahakian, Barbara J., Barker, Roger A., Robbins, Trevor W., Rowe, James B.
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2015
Assuntos:
Archival Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4384955/
https://ncbi.nlm.nih.gov/pubmed/24655598
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.biopsych.2014.01.024
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados